Rangappa Kanchugarakoppal

Rangappa has developed more than 7,500 synthetic small molecules and implemented some of them against therapeutically important proteins. He served as a postdoctoral fellow, research associate, and visiting professor in more than 10 countries. He is a Fellow of: Royal Society of Chemistry, London; National Academy of Sciences, India; Biotech Research Society of India; and Karnataka Science and Technology Academy, India. He has published over 650 research papers in peer reviewed journals, and holds 14 patents for small-molecule inhibitors of therapeutic targets. Three of his patented compounds namely DMBO, NPB, and AMPC have been sold commercially as pharmacological inhibitors of growth factors, BAD protein, TFF3, NF-κB, CXCR4, c-MET, human methionyl-tRNA synthetases, Wnt/β – catenin, EGFR, TGFβ, PI3K/AKT/mTOR, heparanase and many more therapeutically relavant proteins which are constitutively expressed in various human cancers respectively. His publications received over 16000 scientific citations, with an h-index of 66. He has guided 65 candidates for PhD degree.